02/02/2021 News , Publications 0 667


Developed by the company Pocramé, the MEPHIPOINT concept is an emergency analysis and sampler protection tool that has been a real success in 2020 for hospitals facing the Covid-19 pandemic, especially in the Southern Region.

To say that 2020 will remain associated with the Covid-19 pandemic seems to be a given. For Pocramé, this year will also be associated with the takeoff of its business, with a turnover that has doubled in one year. 

The sudden eruption of Sars-Cov-2 all over the world and the exponential needs for PCR tests induced by this pandemic will undoubtedly have accelerated the success of the products proposed by POCRAME. Indeed, from Mephilab to Mephipoint, with the Mephibox as a support, the concept created and marketed by POCRAME perfectly meets the needs of health risk management.

1/ The MEPHILAB or the beginning of the Pocramé concept

It all started with the Mephilab, a mobile emergency analysis laboratory initially created to answer essential questions when in an isolated environment:

- Should the patient be isolated if they are contagious?

- Should the patient be hospitalized if the pathology is serious?

- What specific treatments should be given? 

What is the secret of MephiLab?

This laboratory terminal contains a PCR analyzer capable of discriminating between Sars-Cov-2 and other viruses, but also capable of detecting bacteria in a biological sample or performing vital cardiac tests. It thus embodies a diagnostic strategy: the syndromic approach.

This approach consists of listing a patient's symptoms, comparing them with the known symptoms of one or more diseases and searching the patient's sample for the pathogens that correspond to these diseases. This technique allows to search for several potential pathogens in a very short time. In order to secure the results of the analyses, Pocramé's medical staff remains available to assist in the diagnosis.

CMA/CGM, the world's 4th largest transport operator, and the Ponant cruise line are among the clients who have been won over by this mobile analysis terminal.

According to Dr. Pierre-Yves Lévy, co-founder of Pocramé, "Cruise ships and transport ships present different problems. In the former, there are always doctors and we are close to the coast, but the contagion can take a large scale with several thousand people on board. On the other hand, in cargo ships, there are only about twenty sailors but no doctors".

The MephiLab, which is used by maritime health teams, has equipped some 60 of its container ships over the past two years, in order to be able to make a reliable and precise diagnosis when a crew member or passenger falls ill at sea. Because companies are obviously concerned about the health of their employees and customers. But also because such a tool on board a ship means that a helicopter evacuation or a medical diversion can only be carried out with full knowledge of the facts.

2/ The MEPHIPOINT: from protected sampling to secure analysis

Designed to complete the MEPHILAB, this inflatable structure and its integrated mobile MEPHILAB® infectious diseases laboratory, easy to deploy, is the innovative solution to perform in the same place and in a very short time the secure sampling (nasopharyngeal & capillary blood) and the appropriate test (PCR, TRD) in a test space dedicated to the treatment of potentially contagious samples while preserving the sampler and the environment.

The sampling tubes are decontaminated by a patented proprietary process.

This system allows to relocate and multiply the sampling and analysis as close as possible to the population with three objectives:

  • Speed: installation in less than 30 minutes, results in less than 25 minutes
  • Safety: protection of the sampler (gloves, waterproof wall), of the sample (decontamination via a wall pass), of the working area (by UVc) and of the environment (Hepa filtered air depressurization).
  • Mobility: light, transportable on any terrain.

Used by the healthcare teams of various hospitals, this secure concept has enabled mass testing during the pandemic, to deliver results in a few hours and to take care of the most affected patients as soon as possible.